Evaluation of tolerability with the co-formulation elvitegravir, cobicistat, emtricitabine, and tenofovir disoproxil fumarate for post-HIV exposure prophylaxis

被引：0
|
作者：
Nadia Valin
Laurent Fonquernie
Anne Daguenel
Pauline Campa
Theresita Anthony
Marguerite Guiguet
Pierre Marie Girard
Marie Caroline Meyohas
机构：
[1] Hôpital Saint-Antoine,
[2] Service des Maladies Infectieuses et Tropicales,undefined
[3] Hôpital Saint-Antoine,undefined
[4] Service Pharmacie,undefined
[5] Sorbonne Universités,undefined
[6] UPMC Univ Paris 06,undefined
[7] INSERM,undefined
[8] Institut Pierre Louis d’Epidemiologie et de Santé Publique (IPLESP UMRS 1136),undefined
[9] Sorbonne Universités,undefined
[10] UPMC Univ Paris 06,undefined
来源：
BMC Infectious Diseases | / 16卷
关键词：
Tenofovir Disoproxil Fumarate; Raltegravir; Emtricitabine; Cobicistat; Elvitegravir;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [1] Evaluation of tolerability with the co-formulation elvitegravir, cobicistat, emtricitabine, and tenofovir disoproxil fumarate for post-HIV exposure prophylaxis
    Valin, Nadia
    Fonquernie, Laurent
    Daguenel, Anne
    Campa, Pauline
    Anthony, Theresita
    Guiguet, Marguerite
    Girard, Pierre Marie
    Meyohas, Marie Caroline
    [J]. BMC INFECTIOUS DISEASES, 2016, 16
  • [2] Prophylaxis by doravirine-lamivudine-tenofovir disoproxil fumarate or elvitegravir-cobicistat-emtricitabine-tenofovir alafenamide after sexual exposure to HIV
    Devred, Ines
    Kayembe, Kick
    Valin, Nadia
    Rougier, Hayette
    Shinga, Bruce Wuembulua
    Lambert-Niclot, Sidonie
    Chiarabini, Thibault
    Meyohas, Marie-Caroline
    Lacombe, Karine
    [J]. BMC INFECTIOUS DISEASES, 2023, 23 (01)
  • [3] Prophylaxis by doravirine-lamivudine-tenofovir disoproxil fumarate or elvitegravir-cobicistat-emtricitabine-tenofovir alafenamide after sexual exposure to HIV
    Inès Devred
    Kick Kayembe
    Nadia Valin
    Hayette Rougier
    Bruce Wuembulua Shinga
    Sidonie Lambert-Niclot
    Thibault Chiarabini
    Marie-Caroline Meyohas
    Karine Lacombe
    [J]. BMC Infectious Diseases, 23
  • [4] Efficacy of elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate as treatment for primary or recent HIV infection
    Nozza, Silvia
    Poli, Andrea
    Ripa, Marco
    Galli, Laura
    Chiappetta, Stefania
    Spagnuolo, Vincenzo
    Rovelli, Cristina
    Lazzarin, Adriano
    Castagna, Antonella
    Tambussi, Giuseppe
    [J]. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2017, 72 (02) : 632 - 633
  • [5] Pharmacokinetics of Co-Formulated Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Disoproxil Fumarate After Switch From Efavirenz/Emtricitabine/Tenofovir Disoproxil Fumarate in Healthy Subjects
    Ramanathan, Srini
    Custodio, Joseph M.
    Wei, Xuelian
    Wang, Hui
    Fordyce, Marshall
    Dave, Ami
    Ling, Kah Hiing J.
    Szwarcberg, Javier
    Kearney, Brian P.
    [J]. JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 2016, 72 (03) : 281 - 288
  • [6] Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Disoproxil Fumarate Single Tablet for HIV-1 Infection Treatment
    Olin, Jacqueline L.
    Spooner, Linda M.
    Klibanov, Olga M.
    [J]. ANNALS OF PHARMACOTHERAPY, 2012, 46 (12) : 1671 - 1677
  • [7] Comment on: Efficacy of elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate as treatment for primary or recent HIV infection
    Ambrosioni, Juan
    Mosquera, Maria M.
    Miro, Jose M.
    [J]. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2017, 72 (05) : 1548 - 1549
  • [8] Co-administration of elvitegravir/cobicistat/tenofovir disoproxil fumarate/emtricitabine and atazanavir in treatment-experienced HIV patients
    Biagi, M.
    Badowski, M. E.
    Chiampas, T.
    Young, J.
    Patel, M.
    Vaughn, P.
    [J]. INTERNATIONAL JOURNAL OF STD & AIDS, 2017, 28 (08) : 766 - 772
  • [9] Stribild® (Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Disoproxil Fumarate): A New Paradigm for HIV-1 Treatment
    Manzardo, Christian
    Gatell, Jose M.
    [J]. AIDS REVIEWS, 2014, 16 (01) : 35 - 42
  • [10] Elvitegravir/emtricitabine/tenofovir-disoproxil-fumarate/cobicistat/sildenafil interactionHypotension: case report
    [J]. Reactions Weekly, 2020, 1788 (1) : 104 - 104
12345